ELEV Insider Trading Activity and SEC Form 4 Filings
ELEV insider trading summary
No open-market insider purchases or sales of Elevation Oncology, Inc. (ELEV) have been reported on SEC Form 4 in the past 12 months.
Latest ELEV insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| May 25, 2022 | Robert J Adelman | Insider | Sell | $2.9M (702,737 @ $4.12) |
| May 25, 2022 | Corey S Goodman | Insider | Sell | $2.9M (702,737 @ $4.12) |
| May 25, 2022 | Venbio Global Strategic Gp III, L.P. | Insider | Sell | $2.9M (702,737 @ $4.12) |
| May 25, 2022 | Aaron Royston | Insider | Sell | $2.9M (702,737 @ $4.12) |
| May 25, 2022 | venBio Global Strategic Fund III, L.P. | Insider | Sell | $2.9M (702,737 @ $4.12) |
| Jun 29, 2021 | Aisling Capital Partners IV LLC | 10% Owner | Buy | $3.0M (187,500 @ $16.00) |
| Jun 29, 2021 | Andrew N Schiff | Insider | Buy | $3.0M (187,500 @ $16.00) |
| Jun 29, 2021 | Aisling Capital IV, LP | 10% Owner | Buy | $3.0M (187,500 @ $16.00) |
| Jun 29, 2021 | Aisling Capital Partners IV, LP | 10% Owner | Buy | $3.0M (187,500 @ $16.00) |
| Jun 29, 2021 | Vertex Global HC Fund II Pte. Ltd. | 10% Owner | Buy | $4.0M (250,000 @ $16.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.